These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24856614)

  • 41. The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor.
    Leach K; Davey AE; Felder CC; Sexton PM; Christopoulos A
    Mol Pharmacol; 2011 May; 79(5):855-65. PubMed ID: 21300722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. An Antibody Biosensor Establishes the Activation of the M1 Muscarinic Acetylcholine Receptor during Learning and Memory.
    Butcher AJ; Bradley SJ; Prihandoko R; Brooke SM; Mogg A; Bourgognon JM; Macedo-Hatch T; Edwards JM; Bottrill AR; Challiss RA; Broad LM; Felder CC; Tobin AB
    J Biol Chem; 2016 Apr; 291(17):8862-75. PubMed ID: 26826123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and biological evaluation of a novel series of heterobivalent muscarinic ligands based on xanomeline and 1-[3-(4-butylpiperidin-1-yl)propyl]-1,2,3,4-tetrahydroquinolin-2-one (77-LH-28-1).
    Bonifazi A; Yano H; Del Bello F; Farande A; Quaglia W; Petrelli R; Matucci R; Nesi M; Vistoli G; Ferré S; Piergentili A
    J Med Chem; 2014 Nov; 57(21):9065-77. PubMed ID: 25275964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism.
    Sheffler DJ; Sevel C; Le U; Lovell KM; Tarr JC; Carrington SJ; Cho HP; Digby GJ; Niswender CM; Conn PJ; Hopkins CR; Wood MR; Lindsley CW
    Bioorg Med Chem Lett; 2013 Jan; 23(1):223-7. PubMed ID: 23200253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
    Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
    J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators.
    Han C; Chatterjee A; Noetzel MJ; Panarese JD; Smith E; Chase P; Hodder P; Niswender C; Conn PJ; Lindsley CW; Stauffer SR
    Bioorg Med Chem Lett; 2015 Jan; 25(2):384-8. PubMed ID: 25435150
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
    Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
    Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
    [TBL] [Abstract][Full Text] [Related]  

  • 48. M1 muscarinic allosteric modulators slow prion neurodegeneration and restore memory loss.
    Bradley SJ; Bourgognon JM; Sanger HE; Verity N; Mogg AJ; White DJ; Butcher AJ; Moreno JA; Molloy C; Macedo-Hatch T; Edwards JM; Wess J; Pawlak R; Read DJ; Sexton PM; Broad LM; Steinert JR; Mallucci GR; Christopoulos A; Felder CC; Tobin AB
    J Clin Invest; 2017 Feb; 127(2):487-499. PubMed ID: 27991860
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Allosteric modulators of M
    Widman CJ; Ventresca S; Dietrich J; Elmslie G; Smith H; Kaup G; Wesley A; Doenecke M; Williams FE; Schiefer IT; Ellis J; Messer WS
    Sci Rep; 2024 Jun; 14(1):14901. PubMed ID: 38942828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
    May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
    Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist.
    Langmead CJ; Fry VA; Forbes IT; Branch CL; Christopoulos A; Wood MD; Herdon HJ
    Mol Pharmacol; 2006 Jan; 69(1):236-46. PubMed ID: 16207821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Direct SUMOylation of M1 muscarinic acetylcholine receptor increases its ligand-binding affinity and signal transduction.
    Xu J; Tan P; Li H; Cui Y; Qiu Y; Wang H; Zhang X; Li J; Zhu L; Zhou W; Chen H
    FASEB J; 2019 Mar; 33(3):3237-3251. PubMed ID: 30407877
    [TBL] [Abstract][Full Text] [Related]  

  • 53. On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.
    Christopoulos A; Pierce TL; Sorman JL; El-Fakahany EE
    Mol Pharmacol; 1998 Jun; 53(6):1120-30. PubMed ID: 9614217
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fused heterocyclic M1 positive allosteric modulators.
    Kuduk SD; Di Marco CN; Cofre V; Ray WJ; Ma L; Wittmann M; Seager MA; Koeplinger KA; Thompson CD; Hartman GD; Bilodeau MT
    Bioorg Med Chem Lett; 2011 May; 21(9):2769-72. PubMed ID: 21055928
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.
    Jacobson MA; Kreatsoulas C; Pascarella DM; O'Brien JA; Sur C
    Mol Pharmacol; 2010 Oct; 78(4):648-57. PubMed ID: 20660086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hybrid ortho/allosteric ligands for the adenosine A(1) receptor.
    Narlawar R; Lane JR; Doddareddy M; Lin J; Brussee J; Ijzerman AP
    J Med Chem; 2010 Apr; 53(8):3028-37. PubMed ID: 20345101
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
    Lanzafame AA; Sexton PM; Christopoulos A
    Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties.
    Bridges TM; Brady AE; Kennedy JP; Daniels RN; Miller NR; Kim K; Breininger ML; Gentry PR; Brogan JT; Jones CK; Conn PJ; Lindsley CW
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5439-42. PubMed ID: 18805692
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and Pharmacological Evaluation of Heterocyclic Carboxamides: Positive Allosteric Modulators of the M
    Dallagnol JCC; Khajehali E; van der Westhuizen ET; Jörg M; Valant C; Gonçalves AG; Capuano B; Christopoulos A; Scammells PJ
    J Med Chem; 2018 Apr; 61(7):2875-2894. PubMed ID: 29544056
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae.
    Stewart GD; Sexton PM; Christopoulos A
    Mol Pharmacol; 2010 Aug; 78(2):205-14. PubMed ID: 20466821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.